Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04046185

Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer — ECCT  

Endometrial Cancer Stage I Clinical Trial

Official title:
PD-1 Inhibitor Combined With Progesterone Treatment in Early Stage Endometrial Cancer Patients Who Want to Preserve Fertility

Clinical Trial Summary

We want to make a comparison of PD-1 inhibitor combined with progesterone versus progesterone alone in the treatment of early stage endometrial cancer patients who want to preserve fertility.

Clinical Trial Description

Approximately 63,400 new cases of endometrial cancer are diagnosed annually in China. While the initial treatment for early-stage disease is surgical staging with lymphadenectomy, it is apparently inappropriate for young patients who want to preserve fertility. Currently the standardize treatment for these patients are high-dose progesterone, which will be effective in approximately 40~70% patients. Mirena have been used recently as a new available treatment option, however, no concrete evidence shows it is more effective than the traditional progesterone treatment.

PD-1 inhibitor has been utilized as a salvage treatment in many cancers including ovarian cancer, cervical cancer, lung cancer, gastric cancer and endometrial cancer. As endometrial cancer showed high microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) rates, it is assumed to be highly responsive to PD-1 inhibitor treatment. Published clinical trial results showed that PD-1 inhibitor treatment was effective in 6/24 late-stage endometrial cancer patients, with little or mild side effects. Here we want to investigate the efficacy of PD-1 inhibitor combined with progesterone in early stage endometrial cancer patients who want to preserve fertility. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04046185
Study type Interventional
Source Shanghai First Maternity and Infant Hospital
Contact
Status Not yet recruiting
Phase Early Phase 1
Start date October 1, 2019
Completion date October 1, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03469674 - PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer Phase 3
Not yet recruiting NCT06278857 - SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) Phase 2
Recruiting NCT04792749 - Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer Phase 3
Completed NCT04972682 - [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer N/A
Recruiting NCT05179447 - PROfiling Based Endometrial Cancer Adjuvant Therapy N/A
Recruiting NCT04073706 - Sentinel Node Biopsy in Endometrial Cancer Phase 3
Recruiting NCT04291612 - Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Recruiting NCT06417736 - Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women N/A
Recruiting NCT04839614 - Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia N/A
Completed NCT03580421 - Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO) N/A